MANNKIND CORP (MNKD) Stock Fundamental Analysis

NASDAQ:MNKD • US56400P7069

5.66 USD
+0.03 (+0.53%)
At close: Feb 13, 2026
5.75 USD
+0.09 (+1.59%)
After Hours: 2/13/2026, 4:30:01 PM
Fundamental Rating

5

Taking everything into account, MNKD scores 5 out of 10 in our fundamental rating. MNKD was compared to 523 industry peers in the Biotechnology industry. MNKD has an average financial health and profitability rating. MNKD is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • MNKD had positive earnings in the past year.
  • MNKD had a positive operating cash flow in the past year.
  • MNKD had negative earnings in 4 of the past 5 years.
  • In multiple years MNKD reported negative operating cash flow during the last 5 years.
MNKD Yearly Net Income VS EBIT VS OCF VS FCFMNKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

  • MNKD has a Return On Assets of 5.81%. This is amongst the best in the industry. MNKD outperforms 92.16% of its industry peers.
  • MNKD's Return On Invested Capital of 18.48% is amongst the best of the industry. MNKD outperforms 97.32% of its industry peers.
Industry RankSector Rank
ROA 5.81%
ROE N/A
ROIC 18.48%
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MNKD Yearly ROA, ROE, ROICMNKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100 -150

1.3 Margins

  • MNKD has a better Profit Margin (9.16%) than 90.63% of its industry peers.
  • MNKD has a better Operating Margin (27.48%) than 96.18% of its industry peers.
  • MNKD has a better Gross Margin (78.49%) than 84.70% of its industry peers.
  • MNKD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 27.48%
PM (TTM) 9.16%
GM 78.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
MNKD Yearly Profit, Operating, Gross MarginsMNKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

4

2. Health

2.1 Basic Checks

  • MNKD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for MNKD has been increased compared to 1 year ago.
  • The number of shares outstanding for MNKD has been increased compared to 5 years ago.
  • MNKD has a better debt/assets ratio than last year.
MNKD Yearly Shares OutstandingMNKD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
MNKD Yearly Total Debt VS Total AssetsMNKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • MNKD has an Altman-Z score of -5.26. This is a bad value and indicates that MNKD is not financially healthy and even has some risk of bankruptcy.
  • MNKD has a worse Altman-Z score (-5.26) than 61.38% of its industry peers.
  • MNKD has a debt to FCF ratio of 8.39. This is a slightly negative value and a sign of low solvency as MNKD would need 8.39 years to pay back of all of its debts.
  • MNKD's Debt to FCF ratio of 8.39 is amongst the best of the industry. MNKD outperforms 91.20% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 8.39
Altman-Z -5.26
ROIC/WACC1.52
WACC12.13%
MNKD Yearly LT Debt VS Equity VS FCFMNKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • MNKD has a Current Ratio of 3.29. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.29, MNKD is not doing good in the industry: 60.80% of the companies in the same industry are doing better.
  • A Quick Ratio of 3.04 indicates that MNKD has no problem at all paying its short term obligations.
  • With a Quick ratio value of 3.04, MNKD is not doing good in the industry: 61.57% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.29
Quick Ratio 3.04
MNKD Yearly Current Assets VS Current LiabilitesMNKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

7

3. Growth

3.1 Past

  • MNKD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 174.00%, which is quite impressive.
  • The Revenue has grown by 17.44% in the past year. This is quite good.
  • MNKD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.29% yearly.
EPS 1Y (TTM)174%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%235%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%17.2%

3.2 Future

  • The Earnings Per Share is expected to grow by 52.41% on average over the next years. This is a very strong growth
  • MNKD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.41% yearly.
EPS Next Y-2.25%
EPS Next 2Y4.45%
EPS Next 3Y43.65%
EPS Next 5Y52.41%
Revenue Next Year20.66%
Revenue Next 2Y23.07%
Revenue Next 3Y20.01%
Revenue Next 5Y18.41%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
MNKD Yearly Revenue VS EstimatesMNKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
MNKD Yearly EPS VS EstimatesMNKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 -1 -1.5

5

4. Valuation

4.1 Price/Earnings Ratio

  • MNKD is valuated quite expensively with a Price/Earnings ratio of 40.43.
  • 91.78% of the companies in the same industry are more expensive than MNKD, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 27.67. MNKD is valued slightly more expensive when compared to this.
  • With a Price/Forward Earnings ratio of 64.86, MNKD can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, MNKD is valued cheaply inside the industry as 88.91% of the companies are valued more expensively.
  • MNKD is valuated expensively when we compare the Price/Forward Earnings ratio to 27.69, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 40.43
Fwd PE 64.86
MNKD Price Earnings VS Forward Price EarningsMNKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • MNKD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MNKD is cheaper than 94.84% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, MNKD is valued cheaper than 92.73% of the companies in the same industry.
Industry RankSector Rank
P/FCF 40.06
EV/EBITDA 17.58
MNKD Per share dataMNKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MNKD's earnings are expected to grow with 43.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.45%
EPS Next 3Y43.65%

0

5. Dividend

5.1 Amount

  • No dividends for MNKD!.
Industry RankSector Rank
Dividend Yield 0%

MANNKIND CORP

NASDAQ:MNKD (2/13/2026, 4:30:01 PM)

After market: 5.75 +0.09 (+1.59%)

5.66

+0.03 (+0.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)03-03
Inst Owners57.07%
Inst Owner Change-0.75%
Ins Owners1.59%
Ins Owner Change1%
Market Cap1.74B
Revenue(TTM)313.79M
Net Income(TTM)28.75M
Analysts85.33
Price Target9.8 (73.14%)
Short Float %9.05%
Short Ratio7.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)53.26%
Min EPS beat(2)-100%
Max EPS beat(2)206.52%
EPS beat(4)1
Avg EPS beat(4)19.34%
Min EPS beat(4)-100%
Max EPS beat(4)206.52%
EPS beat(8)2
Avg EPS beat(8)-31.68%
EPS beat(12)5
Avg EPS beat(12)-2.87%
EPS beat(16)6
Avg EPS beat(16)-4.99%
Revenue beat(2)1
Avg Revenue beat(2)-2.11%
Min Revenue beat(2)-4.55%
Max Revenue beat(2)0.33%
Revenue beat(4)3
Avg Revenue beat(4)-0.74%
Min Revenue beat(4)-4.55%
Max Revenue beat(4)0.9%
Revenue beat(8)6
Avg Revenue beat(8)1.65%
Revenue beat(12)8
Avg Revenue beat(12)2.45%
Revenue beat(16)11
Avg Revenue beat(16)3.58%
PT rev (1m)6.13%
PT rev (3m)-7.36%
EPS NQ rev (1m)-22.99%
EPS NQ rev (3m)-43.84%
EPS NY rev (1m)-1.71%
EPS NY rev (3m)-17.43%
Revenue NQ rev (1m)0.88%
Revenue NQ rev (3m)13.28%
Revenue NY rev (1m)-0.21%
Revenue NY rev (3m)5.67%
Valuation
Industry RankSector Rank
PE 40.43
Fwd PE 64.86
P/S 5.54
P/FCF 40.06
P/OCF 35.57
P/B N/A
P/tB N/A
EV/EBITDA 17.58
EPS(TTM)0.14
EY2.47%
EPS(NY)0.09
Fwd EY1.54%
FCF(TTM)0.14
FCFY2.5%
OCF(TTM)0.16
OCFY2.81%
SpS1.02
BVpS-0.15
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 5.81%
ROE N/A
ROCE 22.37%
ROIC 18.48%
ROICexc 48.2%
ROICexgc 50.4%
OM 27.48%
PM (TTM) 9.16%
GM 78.49%
FCFM 13.83%
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
F-Score8
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 8.39
Debt/EBITDA 3.59
Cap/Depr 64.99%
Cap/Sales 1.74%
Interest Coverage 9.12
Cash Conversion 51.63%
Profit Quality 150.89%
Current Ratio 3.29
Quick Ratio 3.04
Altman-Z -5.26
F-Score8
WACC12.13%
ROIC/WACC1.52
Cap/Depr(3y)397.13%
Cap/Depr(5y)337.1%
Cap/Sales(3y)10.78%
Cap/Sales(5y)10.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)174%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%235%
EPS Next Y-2.25%
EPS Next 2Y4.45%
EPS Next 3Y43.65%
EPS Next 5Y52.41%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%17.2%
Revenue Next Year20.66%
Revenue Next 2Y23.07%
Revenue Next 3Y20.01%
Revenue Next 5Y18.41%
EBIT growth 1Y48.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y237.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y386.62%
OCF growth 3YN/A
OCF growth 5YN/A

MANNKIND CORP / MNKD FAQ

What is the fundamental rating for MNKD stock?

ChartMill assigns a fundamental rating of 5 / 10 to MNKD.


Can you provide the valuation status for MANNKIND CORP?

ChartMill assigns a valuation rating of 5 / 10 to MANNKIND CORP (MNKD). This can be considered as Fairly Valued.


Can you provide the profitability details for MANNKIND CORP?

MANNKIND CORP (MNKD) has a profitability rating of 5 / 10.


What are the PE and PB ratios of MANNKIND CORP (MNKD) stock?

The Price/Earnings (PE) ratio for MANNKIND CORP (MNKD) is 40.43 and the Price/Book (PB) ratio is -39.01.